Morgan Stanley raised the firm’s price target on AbbVie (ABBV) to $261 from $255 and keeps an Overweight rating on the shares after the company posted a Q3 beat and raised 2025 revenue and EPS guidance. The company’s key immunology products Skyrizi and Rinvoq “continue to deliver,” while aesthetics and Humira remain soft, the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Ironwood jumps after AbbVie reports Linzess sales beat
- AbbVie Stock (ABBV) Wobbles as Humira Sales Take a Hit, Dims Q3 Glow
- Midday Fly By: Apple, Amazon upbeat reports lift Nasdaq
- AbbVie’s Strong Financial Performance and Growth Potential Justifies Buy Rating
- AbbVie expects strong company growth in 2026 despite Humira erosion